Inflammatory disorder

Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal

5 months ago talkbio0Tagged Advanced phase, biotechnology partnerships, covalent chemistry, Covalent Interaction, Drug Development, Inflammatory disorder, License, Matchpoint Therapeutics, Novartis, oral inhibitors

Novartis; Matchpoint Therapeutics; covalent chemistry; exclusive option and license agreement; inflammatory diseases; oral inhibitors; Advanced Covalent Exploration platform; drug development; biotechnology partnerships

Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma

11 months ago talkbio0Tagged Asthma, COPD, Eczema, Gilead Sciences, Inflammatory disorder, inhibitors, JPM25, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25

Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes

11 months ago talkbio0Tagged Dermatology field, Gilead Sciences, Inflammatory disorder, oral formulations, Partnership, Pharma, STAT6

Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology

Biocon Biologics Secures FDA Approval for YESINTEK, a Biosimilar to Stelara

1 year ago talkbio0Tagged Approved, Biocon, Biological Factors, Inflammatory disorder, Stelara biosimilar, United States Food and Drug Administration, ustekinumab, YESINTEK

Biocon Biologics, FDA approval, YESINTEK, Stelara biosimilar, ustekinumab, inflammatory diseases

Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4

1 year ago talkbio0Tagged allergic diseases, Biotechnology, CAMP4, Inflammatory disorder, IPO, Nasdaq, Upstream Bio

Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases

Merck & Co. Partners with Mestag Therapeutics to Identify Novel Targets for Inflammatory Diseases

1 year ago talkbio0Tagged Co., Collaboration, Fibroblast-immune interactions, Inflammatory disorder, Mestag, Raft, targets

Mestag Therapeutics, Merck & Co., Inflammatory diseases, Fibroblast-immune interactions, RAFT platform, Therapeutic targets, Collaboration agreement

Merck & Co. and Mestag Therapeutics Collaborate on $1.9 Billion Fibroblast Therapy Deal for Inflammatory Diseases

1 year ago talkbio0Tagged Co., Drug Delivery Systems, Drug/, Fibroblast therapies, Identification (Psychology), Inflammatory disorder, Raft

Merck & Co., Mestag Therapeutics, Fibroblast therapies, Inflammatory diseases, $1.9 billion deal, RAFT platform, Drug target identification

Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback

1 year ago talkbio0Tagged Arthritis, Psoriatic, Biosciences, Crohn 's disease, Drug Development, Inflammatory disorder, Inhibitor, Phase 2 Failure, Psoriasis, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.